DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

Times and Dates: 8 a.m.–6 p.m., October 24, 2007; 8 a.m.–5 p.m., October 25, 2007

Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton Road, NE., Building 19, Kent ''Oz'' Nelson Auditorium, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

Matters To Be Discussed: The agenda will include discussions on Influenza Vaccines; Meningococcal Conjugate Vaccine; Childhood and Adolescent Immunization Schedule—2007; Immunization Schedule for HIV-Infected Adults; Pediatric Use of Pneumococcal Vaccines; Updates on Combination Vaccines, Vaccine Supply and Hepatitis B Vaccine; Immunization Safety Office; HPV Vaccines; Rotavirus Vaccine; and departmental updates. There may be possible VFC voting on the Influenza and Meningococcal Vaccines.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Tonica Gleaton, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road, NE., (E–05), Atlanta, Georgia 30333, Telephone (404) 639–8836, Fax (404) 639–8905.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and the Agency for Toxic Substance and Disease Registry.

Dated: September 26, 2007.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E7–19393 Filed 10–1–07; 8:45 am]

BILLING CODE 4160–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, Coordinating Center for Infectious Diseases (CCID)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned committee.

Times and Dates: 9 a.m.–5 p.m., October 31, 2007; 8:30 a.m.–3:30 p.m., November 1, 2007

Place: CDC, Building 19, 1600 Clifton Road, NE., Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The Board of Scientific Counselors, Coordinating Center for Infectious Diseases (CCID), provides advice and guidance to the Director, CDC, and Director, CCID, in the following areas: program goals and objectives, strategies, program organization and resources for infectious disease prevention and control, and program priorities.

Matters To Be Discussed: Agenda items will include:

1. Breakout Group Discussions:

A. Laboratory Preparedness and Sustainability, National Center for Prevention, Detection, and Control of Infectious Diseases.

B. Influenza Diagnostics Program, National Center for Immunization, and Respiratory Diseases (NCIRD).

C. Immunization Assessment and Coverage, NCIRD.

D. Strategic Surveillance, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

E. Infectious Disease Ecology, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

2. Surveillance Systems.

3. CCID Updates.

4. Budget Updates.

Other agenda items include announcements and introductions, follow-up on actions recommended by the Board from March 2007, consideration of future directions, goals, and recommendations.

Agenda items are subject to change as priorities dictate.

Written comments are welcome and should be received by the contact person listed below prior to the opening of the meeting.

Contact Person for More Information: Harriette Lynch, Office of the Director, NCID, CDC, Mailstop A–45, 1600 Clifton Road, NE., Atlanta, Georgia 30333, e-mail: *HLynch@cdc.gov,* telephone 404/639–4035.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: September 26, 2007.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E7–19403 Filed 10–1–07; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2007N–0014]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Submission of Petitions: Food Additive, Color Additive (Including Labeling), and Generally Recognized as Safe Affirmation; Electronic Submission Using Food and Drug Administration Forms 3503 and 3504

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Submission of Petitions: Food Additive, Color Additive (Including Labeling), and Generally Recognized as Safe Affirmation; Electronic Submission Using Food and Drug Administration Forms 3503 and 3504'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief Information Officer (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of April 25, 2007 (72 FR 20553), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0016. The approval expires on August 31, 2010. A copy of the supporting statement for this information collection is available on the Internet at *http://www.fda.gov/ohrms/dockets.*